Amyris and ImmunityBio have completed a previously announced joint venture agreement to accelerate the commercialization of a next-generation COVID-19 vaccine.   As part of the joint venture, the two companies combine important vaccine technology and manufacturing capabilities. Upon completion of successful human trials and regulatory approval, the joint venture’s goal is to start delivering the second generation vaccine in 2022 as soon as is practically possible with a goal of delivering ...